AI English summary of an SEC filing — figures as filed
Becton Dickinson BDXThe company said preliminary unaudited revenue for the 3 months ended September 30, 2025 was approximately $5.9 billion, representing an estimated increase of approximately 8.3% on a reported basis, 7.0% on a currency-neutral basis and 3.9% on an organic basis.
Key points
AI summaryThe company said preliminary unaudited revenue for the 3 months ended September 30, 2025 was approximately $5.9 billion, representing an estimated increase of approximately 8.3% on a reported basis, 7.0% on a currency-neutral basis and 3.9% on an organic basis.
The company said preliminary unaudited revenue for the full year 2025 fiscal year (12 months) was approximately $21.8 billion, representing an estimated increase of approximately 8.2% on a reported basis, 7.7% on an adjusted currency-neutral basis and 2.9% on an organic basis.
Becton Dickinson said Executive Vice President and Chief Financial Officer Christopher J. DelOrefice will resign effective December 5, 2025, and Vitor Roque will serve as interim Chief Financial Officer until a permanent successor is named. The company said it is conducting a search to identify a permanent Chief Financial Officer.
The company said it expects full year 2025 adjusted diluted earnings per share to be at or above the midpoint of its previously issued guidance. It said the impact on its business this quarter in Pharmaceutical Systems vaccines and Biosciences academic and government research areas was greater than anticipated due to the dynamic macro environment.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
2025 Fiscal Q4 Preliminary Revenue
The company said preliminary unaudited revenue for the 3 months ended September 30, 2025 was approximately $5.9 billion, representing an estimated increase of approximately 8.3% on a reported basis, 7.0% on a currency-neutral basis and 3.9% on an organic basis.
Source · Based on the filing body and exhibits
Full Year 2025 Preliminary Revenue
The company said preliminary unaudited revenue for the full year 2025 fiscal year (12 months) was approximately $21.8 billion, representing an estimated increase of approximately 8.2% on a reported basis, 7.7% on an adjusted currency-neutral basis and 2.9% on an organic basis.
Source · Based on the filing body and exhibits
Chief Financial Officer Transition and Interim Successor
Becton Dickinson said Executive Vice President and Chief Financial Officer Christopher J. DelOrefice will resign effective December 5, 2025, and Vitor Roque will serve as interim Chief Financial Officer until a permanent successor is named. The company said it is conducting a search to identify a permanent Chief Financial Officer.
Source · Based on the filing body and exhibits
Adjusted Diluted EPS Outlook and Macro Environment
The company said it expects full year 2025 adjusted diluted earnings per share to be at or above the midpoint of its previously issued guidance. It said the impact on its business this quarter in Pharmaceutical Systems vaccines and Biosciences academic and government research areas was greater than anticipated due to the dynamic macro environment.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…